More Good News for Eli Lilly Sends the Stock Even Higher
Lilly's experimental GLP-1 is effective in treating osteoarthritic knee pain.
Eli Lilly (LLY) experienced a surge in its stock price as promising results from clinical trials of its experimental GLP-1 drug, retatrutide, were announced on Monday. The phase 3 trials conducted at Northwestern University demonstrated that the drug effectively reduced knee osteoarthritis (OA) pain and led to significant weight loss.
Retatrutide's potential approval by the FDA for both weight loss and OA pain relief has generated considerable excitement in the market. Additionally, Lilly has partnered with Hims & Hers Health to expand access to two other GLP-1 drugs, Zepbound and Foundayo, on their platform. Furthermore, Foundayo has shown promise in reducing the severity of obstructive sleep apnea by up to 44% in a phase 3 program.
Despite a 51% increase in the stock's price over the past year, the healthcare giant remains a strong contender in the rapidly expanding GLP-1 drug market, with sales up 39% and earnings per share growing 16% in the third quarter. The potential benefits of GLP-1 drugs extend beyond weight loss and pain relief, as research continues to uncover their anti-inflammatory and metabolic effects, which could lead to treatments for various health conditions, including cardiovascular, kidney, liver, arthritis, and sleep apnea disorders.
Analysts predict that the market for GLP-1 drugs may bring about a significant shift in healthcare, making Lilly a compelling investment opportunity.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
